Bosutinib
- Generic Name
- Bosutinib
- Brand Names
- Bosulif
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29Cl2N5O3
- CAS Number
- 380843-75-4
- Unique Ingredient Identifier
- 5018V4AEZ0
- Background
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion prote...
- Indication
用于治疗对既往治疗无效的慢性、加速期或急变期Ph+的慢性粒细胞白血病（CML）患者。
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Study of Olverembatinib (HQP1351) in Patients With CP-CML
- Conditions
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT06423911
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT06297161
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT05363488
- Locations
- 🇬🇧
eatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
- Conditions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1484
- Registration Number
- NCT05286528
- Locations
- 🇭🇺
Pfizer, Budapest, Hungary
Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT05032690
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 404
- Registration Number
- NCT04971226
- Locations
- 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸Texas Oncology Austin, Dallas, Texas, United States
🇺🇸Texas Oncology Texas Onc - Amarillo, Dallas, Texas, United States
Asciminib Roll-over Study
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 347
- Registration Number
- NCT04877522
- Locations
- 🇺🇸
Michigan Med University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
🇺🇸Oregon Health Sciences University, Portland, Oregon, United States
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 100
- Registration Number
- NCT04578847
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 60
- Registration Number
- NCT04258943
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Children's Specialty Center of Nevada II, Las Vegas, Nevada, United States
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT03885830
- Locations
- 🇺🇸
UNC Hospital, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.